Prosecution Insights
Last updated: October 02, 2026
Application No. 18/694,093

DOSING OPERATION SPEED DETECTION WITH ELECTRONIC SYSTEM FOR A DRUG DELIVERY DEVICE

Final Rejection §112
Filed
Mar 21, 2024
Priority
Sep 24, 2021 — EU 21315170.7 +1 more
Examiner
BOUCHELLE, LAURA A
Art Unit
Tech Center
Assignee
Sanofi S.A.
OA Round
2 (Final)
80%
Grant Probability
Favorable
3-4
OA Rounds
8m
Est. Remaining
91%
With Interview

Examiner Intelligence

Grants 80% — above average
80%
Career Allowance Rate
980 granted / 1222 resolved
+20.2% vs TC avg
Moderate +11% lift
Without
With
+10.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
42 currently pending
Career history
1249
Total Applications
across all art units

Statute-Specific Performance

§101
1.3%
-38.7% vs TC avg
§103
47.5%
+7.5% vs TC avg
§102
25.4%
-14.6% vs TC avg
§112
15.8%
-24.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1222 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Arguments Applicant's arguments filed 8/25/2026 have been fully considered. Regarding the objection to claim 9, Applicant’s arguments are convincing. The amendment to the claim overcomes the objection and the objection is therefore withdrawn. Regarding the rejections under 102, Applicant’s arguments are convincing. The examiner agrees that the claims have been amended to include subject matter previously indicated allowable. However, the examiner notes that claim 3 does not include all of the limitations of claim 1 and therefore includes subject matter that lacks antecedent basis. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 3, 7, 8, 14 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 3 recites the limitation "the first speed threshold" in lines 11-12. There is insufficient antecedent basis for this limitation in the claim. Claim 7 recites the limitation "the first sample rate" in line 16. There is insufficient antecedent basis for this limitation in the claim. Claim 8 inherits the deficiency of claim 7. Claim 14 recites the limitation "the overall specific movement" in lines 1-2. There is insufficient antecedent basis for this limitation in the claim. Allowable Subject Matter Claims 1, 2, 5, 6, 9, 11-13, 15-17 are allowed. Claims 3, 7, 8, 14 are allowable over the prior art of record but for the 112(b) rejections above. The following is a statement of reasons for the indication of allowable subject matter: see prior office actions. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to LAURA A BOUCHELLE whose telephone number is (571)272-2125. The examiner can normally be reached Mon-Fri 8:00-5:00 CST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Bhisma Mehta can be reached at 571-272-3383. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. LAURA A. BOUCHELLE Primary Examiner Art Unit 3783 /LAURA A BOUCHELLE/Primary Examiner, Art Unit 3783
Read full office action

Prosecution Timeline

Mar 21, 2024
Application Filed
May 27, 2026
Non-Final Rejection mailed — §112
Aug 25, 2026
Response Filed
Sep 24, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12746152
INJECTION DEVICE WITH BOTH LINEAR AND ROTARY INDEPENDENT MOTOR DRIVES
3y 7m to grant Granted Sep 29, 2026
Patent 12728183
MEDICAL SYSTEM INCLUDING STEERABLE CATHETER AND METHOD OF MANUFACTURING
3y 11m to grant Granted Sep 08, 2026
Patent 12721750
CONTROLLED INJECTION BETWEEN TWO TISSUE LAYERS OF THE HUMAN EYE
3y 9m to grant Granted Sep 01, 2026
Patent 12714782
INFUSION PUMP WITH ADD-ON MODULES
2y 9m to grant Granted Aug 25, 2026
Patent 12708707
System and Method for Pressure Management for a Drug Delivery Device
4y 9m to grant Granted Aug 18, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
80%
Grant Probability
91%
With Interview (+10.7%)
3y 2m (~8m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1222 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month